Codexis (CDXS) Restructuring Costs (2022 - 2023)

Codexis (CDXS) posted quarterly Restructuring Costs of $3.1 million for Q3 2023, up 4261.11% quarter-over-quarter from $72000.0 in Q2 2023.

Codexis (CDXS) Restructuring Costs (2022 - 2023) Analysis & Trends

Codexis' Restructuring Costs history runs 2 years deep, the most recent figure standing at $3.1 million for Q3 2023.

In Q3 2023, Restructuring Costs changed N/A year-over-year to $3.1 million; the TTM figure through Jun 2024 stood at $3.1 million (down 5.16% YoY), while the FY2025 annual figure was $3.4 million, changed N/A from the prior year.
Restructuring Costs for Q3 2023 stood at $3.1 million, up from $72000.0 in the prior quarter.
The five-year high for Restructuring Costs was $3.2 million in Q4 2022, with the low at $72000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Codexis	143.86 Mn	88.95 Mn	11.40 Mn

Download Data